# Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma

> **NCT01355445** · PHASE2 · COMPLETED · sponsor: **Centre Oscar Lambret** · enrollment: 120 (actual)

## Conditions studied

- RHABDOMYOSARCOMA

## Interventions

- **DRUG:** Vincristine, Irinotecan
- **DRUG:** Vincristine, Irinotecan, Temozolomide

## Key facts

- **NCT ID:** NCT01355445
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2018-06
- **Final completion:** 2019-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355445, "Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01355445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*